p53 is one of the most important regulators of cell proliferation and differentiation and of programmed cell death, triggering growth arrest and/or apoptosis in response to different cellular stress signals. The sequence-specific DNA-binding function of p53 protein can be activated by several different stimuli that modulate the C-terminal domain of this protein. The predominant mechanism of activation of p53 sequence-specific DNA binding is phosphorylation at specific sites. For example, phosphorylation of p53 by PKC (protein kinase C) occurs in undamaged cells, resulting in masking of the epitope recognized by monoclonal antibody PAb421, and presumably promotes steady-state levels of p53 activity in cycling cells. In contrast, phosphorylation by cdk2 (cyclin-dependent kinase 2)/cyclin A and by the protein kinase CK2 are both enhanced in DNA-damaged cells. We determined whether one mechanism to account for this mutually exclusive phosphorylation may be that each phosphorylation event prevents modification by the other kinase. We used non-radioactive electrophoretic mobility shift assays to show that C-terminal phosphorylation of p53 protein by cdk2/cyclin A on Ser315 or by PKC on Ser378 can efficiently stimulate p53 binding to DNA in vitro, as well as binding of the monoclonal antibody Bp53-10, which recognizes residues 371-380 in the C-terminus of p53. Phosphorylation of p53 by CK2 on Ser392 induces its DNA-binding activity to a much lower extent than phosphorylation by cdk2/cyclin A or PKC. In addition, phosphorylation by CK2 strongly inhibits PKC-induced activation of p53 DNA binding, while the activation of p53 by cdk2/cyclin A is not affected by CK2. The presence of CK2-mediated phosphorylation promotes PKC binding to its docking site within the p53 oligomerization domain, but decreases phosphorylation by PKC, suggesting that competition between CK2 and PKC does not rely on the inhibition of PKC-p53 complex formation. These results indicate the crucial role of p53 C-terminal phosphorylation in the regulation of its DNA-binding activity, but also suggest that antagonistic relationships exist between different stress signalling pathways.

Masaryk Memorial Cancer Institute Zlutý kopec 7 CZ 656 53 Brno Czech Republic

Zobrazit více v PubMed

Cell. 1995 Jun 30;81(7):1021-9 PubMed

J Mol Biol. 1995 Apr 21;248(1):58-78 PubMed

Oncogene. 1996 Feb 15;12(4):921-30 PubMed

J Photochem Photobiol B. 1996 Aug;35(1-2):45-52 PubMed

Nucleic Acids Res. 1996 Sep 15;24(18):3560-7 PubMed

J Biol Chem. 1996 Nov 15;271(46):29380-5 PubMed

Oncogene. 1999 Nov 1;18(45):6145-57 PubMed

Oncogene. 1999 Dec 13;18(53):7644-55 PubMed

FEBS Lett. 2000 Jan 21;466(1):91-5 PubMed

Biochem Biophys Res Commun. 2000 Jan 27;267(3):934-9 PubMed

J Immunol Methods. 2000 Apr 3;237(1-2):51-64 PubMed

J Mol Biol. 2000 Jul 14;300(3):503-18 PubMed

Nature. 2000 Nov 16;408(6810):307-10 PubMed

J Cell Biochem. 2001;81(1):172-83 PubMed

EMBO Rep. 2001 Feb;2(2):139-44 PubMed

J Biol Chem. 2001 Apr 20;276(16):12654-9 PubMed

J Biol Chem. 2001 May 11;276(19):15650-8 PubMed

Eur J Biochem. 2001 May;268(10):2763 PubMed

J Biol Chem. 2001 Feb 16;276(7):4699-708 PubMed

Oncogene. 2001 Jun 7;20(26):3341-7 PubMed

Oncogene. 2001 Jun 21;20(28):3597-608 PubMed

Folia Biol (Praha). 2001;47(4):148-51 PubMed

Br J Cancer. 2001 Dec 14;85(12):1813-23 PubMed

Biochemistry. 2002 Jan 8;41(1):170-8 PubMed

J Immunol Methods. 2002 Sep 15;267(2):227-35 PubMed

J Mol Biol. 2002 Oct 4;322(5):917-27 PubMed

J Biol Chem. 2003 Apr 11;278(15):13431-41 PubMed

EMBO Rep. 2003 Aug;4(8):787-92 PubMed

Mol Cell Biol. 2003 Dec;23(23):8846-61 PubMed

J Cell Sci. 1992 Jan;101 ( Pt 1):183-9 PubMed

J Immunol Methods. 1992 Jul 6;151(1-2):237-44 PubMed

J Invest Dermatol. 1992 Aug;99(2):221-6 PubMed

Cell. 1992 Nov 27;71(5):875-86 PubMed

Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11627-31 PubMed

Cell Growth Differ. 1994 Mar;5(3):329-40 PubMed

Oncogene. 1994 Nov;9(11):3249-57 PubMed

J Biol Chem. 1994 Nov 25;269(47):29579-87 PubMed

Curr Biol. 1994 Oct 1;4(10):865-75 PubMed

J Biol Chem. 1995 Mar 10;270(10):5405-11 PubMed

Eur J Biochem. 1997 May 1;245(3):684-92 PubMed

Biochemistry. 1997 Aug 19;36(33):10117-24 PubMed

Cell. 1997 Aug 22;90(4):595-606 PubMed

Mol Cell Biol. 1997 Oct;17(10):5923-34 PubMed

Mol Cell Biol. 1997 Nov;17(11):6255-64 PubMed

Mol Cell Biol. 1997 Dec;17(12):7220-9 PubMed

Oncogene. 1997 Oct;15(18):2201-9 PubMed

Biochem Biophys Res Commun. 1998 Apr 17;245(2):514-8 PubMed

Nat Genet. 1998 Jun;19(2):175-8 PubMed

Oncol Res. 1998;10(2):55-7 PubMed

Oncogene. 1998 Aug 27;17(8):1045-52 PubMed

Mol Cell Biochem. 1999 Jan;191(1-2):111-20 PubMed

FEBS Lett. 1999 Mar 26;447(2-3):160-6 PubMed

J Biol Chem. 1995 Jul 28;270(30):18165-74 PubMed

Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage

Characterization of p53 Family Homologs in Evolutionary Remote Branches of Holozoa

Evidence for allosteric effects on p53 oligomerization induced by phosphorylation

Enzyme-Linked Electrochemical Detection of PCR-Amplified Nucleotide Sequences Using Disposable Screen-Printed Sensors. Applications in Gene Expression Monitoring